Detalles de la búsqueda
1.
Evidence for an alternative fatty acid desaturation pathway increasing cancer plasticity.
Nature
; 566(7744): 403-406, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30728499
2.
Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
J Biol Chem
; 295(11): 3431-3446, 2020 03 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-32005668
3.
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
Int J Cancer
; 145(5): 1346-1357, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30807645
4.
Correction: Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12.
J Biol Chem
; 295(48): 16464-16467, 2020 Nov 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-33246941
5.
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Cell Chem Biol
; 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537632
6.
Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Biol Chem
; 393(12): 1449-55, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-23667902
7.
A Small Molecule-Drug Conjugate (SMDC) Consisting of a Modified Camptothecin Payload Linked to an αVß3 Binder for the Treatment of Multiple Cancer Types.
Cancers (Basel)
; 14(2)2022 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35053556
8.
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo.
Breast Cancer Res Treat
; 127(3): 649-57, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20635136
9.
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.
J Cell Mol Med
; 14(12): 2760-70, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19863693
10.
Distinct functionality of tumor cell-derived gelatinases during formation of liver metastases.
Mol Cancer Res
; 6(3): 341-51, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18337444
11.
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling.
Cancer Res
; 67(18): 8615-23, 2007 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17875701
12.
Optimization of PDE3A Modulators for SLFN12-Dependent Cancer Cell Killing.
ACS Med Chem Lett
; 10(11): 1537-1542, 2019 Nov 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31749907
13.
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Mol Cancer Ther
; 17(11): 2285-2296, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30115664
14.
Reduction of experimental human fibrosarcoma lung metastasis in mice by adenovirus-mediated cystatin C overexpression in the host.
Cancer Res
; 65(19): 8608-12, 2005 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16204025
15.
Antimetastatic activity of a novel mechanism-based gelatinase inhibitor.
Cancer Res
; 65(9): 3523-6, 2005 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15867341
16.
Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells.
Cell Death Dis
; 8(3): e2716, 2017 03 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-28358377
17.
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Mol Cancer Ther
; 16(5): 893-904, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28292941
18.
Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model.
Cancer Res
; 62(19): 5543-50, 2002 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12359766
19.
Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Cancer Res
; 76(21): 6331-6339, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27543601
20.
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth.
Cancer Metab
; 3: 11, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26500770